Unlocking the Future: The Growing Significance of AI in Biopharma and BD&L

A panel discussion with:

• Ed Kivell, Life Sciences lead EMEA/APAC, AlphaSense
• Matthias Mullenbeck, SVP, Head Global Business Development & Alliance Management, Merck
• Olivia Cavlan, Chief Corporate Development and Strategy Officer, Alchemab Therapeutics
• Martin-Immanuel Bittner, Co-Founder and CEO, Arctoris
• Marko Kuisma, Partner, Innovestor

In the rapidly evolving landscape of biopharmaceuticals, the integration of artificial intelligence (AI) has become pivotal. Join us as we explore the remarkable impact of AI on various facets of the biopharma industry, with a particular focus on its transformative role in Business Development and Licensing (BD&L).

Discover how AI-powered solutions are reshaping the way biopharma companies identify opportunities, enhance decision-making, and drive innovation.

In partnership with Alphasense

Staying up to date on clinical trial pipelines, evolving markets, disease areas, and BD&L opportunities is highly time-consuming and fragmented. AlphaSense ensures you find the information you need faster and before it’s on anyone else’s radar.

www.alpha-sense.com

The LSX channel features sessions from LSX events, where our mission is to connect senior #biotech, #medtech & #healthtech executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses.

Subscribe to our channel for more videos.

Follow us on Twitter:   / lsxleaders  

Visit us at www.lsxleaders.com